Last reviewed · How we verify
LY2603618
At a glance
| Generic name | LY2603618 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
- A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors (PHASE1)
- C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors (PHASE1)
- A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine (PHASE1)
- Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer (PHASE1)
- A Study in Non Small Cell Lung Cancer (PHASE1, PHASE2)
- A Study for Participants With Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2603618 CI brief — competitive landscape report
- LY2603618 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI